bluebird bio received a notice from Nasdaq on September 30, 2024, indicating non-compliance with the minimum bid price requirement of $1.00 per share, as its stock has traded below this threshold for 32 consecutive business days. The company has been granted a 180-day grace period until March 31, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days.If unable to meet the requirement by March 31, 2025, the company may be eligible for an additional 180-day compliance period by transferring to the Nasdaq Capital Market. bluebird bio is actively monitoring its stock price and considering various options, including seeking shareholder approval for a reverse stock split at its 2024 Annual Meeting. The notice has no immediate effect on the company's listing, which continues to trade under "BLUE" on the Nasdaq Global Select Market.

bluebird bio received a notice from Nasdaq on September 30, 2024, indicating non-compliance with the minimum bid price requirement of $1.00 per share, as its stock has traded below this threshold for 32 consecutive business days. The company has been granted a 180-day grace period until March 31, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days.If unable to meet the requirement by March 31, 2025, the company may be eligible for an additional 180-day compliance period by transferring to the Nasdaq Capital Market. bluebird bio is actively monitoring its stock price and considering various options, including seeking shareholder approval for a reverse stock split at its 2024 Annual Meeting. The notice has no immediate effect on the company's listing, which continues to trade under "BLUE" on the Nasdaq Global Select Market.